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Abstract
Mammalian somatic cells can be directly reprogrammed into induced pluripotent stem cells
(iPSCs) by introducing defined sets of transcription factors. Somatic cell reprogramming involves
epigenomic reconfiguration, conferring iPSCs with characteristics similar to embryonic stem cells
(ESCs). Human ES cells contain 5-hydroxymethylcytosine (5hmC), which is generated through
the oxidation of 5-methylcytosine by the TET enzyme family. Here we show that 5hmC levels
increase significantly during reprogramming to human iPSCs mainly due to TET1 activation, and
this hydroxymethylation change is critical for optimal epigenetic reprogramming, but does not
compromise primed pluripotency. Compared with hES cells, we find iPS cells tend to form large-
scale (100 kb-1.3 Mb) aberrant reprogramming hotspots in subtelomeric regions, most of which
display incomplete hydroxymethylation on CG sites. Strikingly, these 5hmC aberrant hotspots
largely coincide (~80%) with aberrant iPS-ES non-CG methylation regions. Our results suggest
that TET1-mediated 5hmC modification could contribute the epigenetic variation of iPSCs and
iPSC-hESC differences.
Pluripotency is defined as a stem cell state with the potential to differentiate into any of the
three germ layers. Somatic cells can be reprogrammed to a pluripotent state by defined
factors such as OCT4, SOX2, KLF4, c-MYC, NANOG and LIN281-3. These iPSCs are
extremely similar to ESCs. During the reprogramming process, the global epigenetic
landscape in somatic cells has to be reset to reach a pluripotent state via DNA methylation/
demethylation and chromatin remodelling processes.
Besides 5-methylcytosine (5mC), which is known to display dynamic changes during early
embryonic and germ cell development as well as the reprogramming process, the
mammalian genome also contains 5hmC, which is generated by oxidation of 5mC by the
TET family of enzymes4, 5. The Tet proteins function in ESCs regulation, myelopoiesis and
zygote development6-10. 5hmC was found to be widespread in many tissues and cell types at
different levels11, 12. Particularly, 5hmC is abundant in the central nervous system and
ESCs. Several reports have explored the genome-wide distribution of 5hmC modification in
mES cells and hES cells, and suggest that it is enriched in gene bodies and enhancers13, 14.
Reprogramming toward pluripotency involves a dynamic epigenetic modification process.
5hmC has been implicated in the DNA demethylation process15, pointing to a potential role
for 5hmC modification during reprogramming toward pluripotency. Thus, understanding the
dynamic 5hmC changes during reprogramming will provide additional insight into somatic
cell reprogramming mechanisms.
Multiple studies suggest there are subtle yet substantial genetic and epigenetic differences
between iPS cells and hES cells16, 17. The current consensus is that iPS cells and ES cells
are two overlapping classes of heterogeneous cells, with iPS cells being more variable than
hES cells18. Although iPS cells and hES cells are functionally equivalent in general, the
subtle genetic and epigenetic differences could lead to functional consequences among
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individual lines. Previous study of the base-resolution methylomes of iPSCs and ESCs
identified differentially methylated regions (DMRs) between iPSCs and ESCs, consisting of
CG-DMRs and non-CG-DMRs16, 17. However, the traditional bisulfite sequencing
technique they used could not distinguish 5mC from 5hmC19, which means how these
DMRs are caused by hydroxymethylation differences remains unknown.
Here we show that 5hmC levels increase significantly during reprogramming to human
iPSCs mainly due to TET1 activation, and this hydroxymethylation change is critical for
optimal epigenetic reprogramming. We found that during reprogramming extensive
genome-wide 5hmC modification occurs. Importantly, we identified specific aberrant
reprogramming hotspots in iPS cells, which cluster on a large-scale (100kb-1.3Mb) at
subtelomeric regions bearing incomplete CG hydroxymethylation. These hotspots largely
overlap with aberrant non-CG methylation hotspots, suggesting hydroxymethylation
contributes to the epigenetic difference between iPS cells and hES cells.
RESULTS
TET1-mediated hydroxymethylation plays a critical role during reprogramming to
pluripotency in human cells
DNA methylation is a major barrier to iPS cell reprogramming. Several lines of evidence
suggest that 5hmC is involved in the process of DNA demethylation20, 21. We found a
significant increase of 5hmC level in human iPS cells compared to their original fibroblasts,
with the amount in iPSCs being similar to hES cells (Fig. 1a).
TET family proteins (TET1, TET2 and TET3) could convert 5mC to 5hmC6. We found a
statistically significant increase of TET1 and TET3; with a more dramatically increase of
TET1, and a slight decrease of TET2 expression (Fig. 1b). RNA-seq reveals that TET1 is at
a comparable level to NANOG in pluripotent cells, but the expression of TET2 and TET3
are significantly lower (Fig. 1c). Depletion of TET1 but not TET2 and TET3 by siRNA
could significantly decrease total 5hmC levels in human iPS cells (Fig. 1d and
Supplementary Fig. S1a,b). Therefore, we conclude that TET1 is the main TET protein
regulating hydroxymethylation during human iPS cells reprogramming.
Because cellular reprogramming is an epigenetic state reconfiguring process, we next asked
whether TET1-mediated hydroxymethylation changes are critical in human iPSC
reprogramming. Introducing shTET1 lentivirus with “Yamanka factors” infection could
decrease alkaline phosphatase positive colonies when compared with equal titer shControl
lentivirus transduction (Fig. 1e,f and Supplementary Fig. S1c,d). shTET1 treated colonies
during reprogramming can be further stably maintained, showing decreased TET1 levels,
but similar pluripotent gene expression levels compared with iPSCs (Fig. 1g). Furthermore,
iPS cells depleted with TET1 maintained a normal undifferentiated stem cell morphology,
are positive for alkaline phosphatase, expressed same level pluripotent related factors and
stained positive for the pluripotency markers such as NANOG, SOX2, TRA-1-81 (Fig. 1h
and Supplementary Fig. S1e-g). Therefore, TET1-mediated hydroxymethylation
modification is required for optimal induction of iPSCs, but does not compromise the
essential pluripotency of human stem cells.
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5hmC epigenomic landscape during reprogramming
We employed 5hmC Capture-Seq to assess genome-wide 5-hmC distributions during
reprogramming11. The cell lines and sequencing statistics are summarized on
Supplementary Table S2 and S3. Pearson correlation and cluster analysis of the global
5hmC modification pattern suggests a significant difference between iPS cells and
fibroblasts (Fig. 2a and Supplementary Table S4).
Based on a negative binomial model for testing differential expression of sequencing data22,
we found 267,664 regions in the genome showing differential 5-hydroxymethylation
modification between iPS cells and fibroblast (false discovery rate (FDR): 0.01), which
denoted as differential 5-hydroxymethylated regions (DhMRs). Among them, 231,866 are
hyperDhMRs (5hmC level is higher in iPS cells), and 35,798 are hypoDhMRs (5hmC level
is lower in iPS cells) (Fig. 2b). The hyperDhMRs show higher gain of 5hmC than the loss of
5hmC observed at hypoDhMRs (Fig. 2c). The hyperDhMRs are distributed across all
autosomes, but largely missing in sex chromosomes (Fig. 2d). Particularly, of the top 20000
hyperDhMRs (ranked by adjusted p-values), they have a higher probability (p<0.0001) of
being located in the telomere proximal regions (Fig. 2e), as shown by example of
Chromosome 1 and Chromosome X (Fig. 2f).
5hmC is bi-directionally correlated with DNA methylation changes and associated with
pluripotency related gene networks
The analysis described above suggests a global hydroxymethylation change during
reprogramming. 5hmC has been suggested linked with gene expression in ES cells and
neurons13, 14, 23-26. To assess the correlation between 5hmC modifications and gene
expression changes during reprogramming, we stratified genes into 9 categories based on
gene expression changes between iPS cells and fibroblasts (category 1: high expression in
iPS cells, low expression in fibroblast; category 2: medium expression in iPS cells, low
expression in fibroblast, etc). We then quantified the amount of 5hmC around transcription
start site (TSS). As a result, those 9 categories can be clustered into 3 distinct patterns (Fig.
3a). Of note, most expressed genes during reprogramming show a bimodal distribution with
a depletion of 5hmC in TSS sites, whereas genes remain silenced after reprogramming show
a peak in TSS sites. Among 3 clusters, cluster1 has the lowest 5hmC levels in TSS; cluster 3
has the highest levels of 5hmC in TSS, but has lowest 5hmC levels in gene bodies (Fig. 3b).
We then examined the correlation between absolute amount of transcripts and 5hmC
enrichment. We noticed that hyperDhMRs tend to form bimodal distribution associated with
gene activity in iPS cells, with the lowest level similar to the level in fibroblast in TSS
regions (Fig. 3c and Supplementary Fig. S2). TES regions also show a bimodal distribution,
the depletion is more dramatic in a narrower region centred on TES (Supplementary Fig.
S2). However, compared with hypoDhMRs, hyperDhMRs are more enriched in TSS, exons
and TES (Supplementary Fig. S3a). We observed a significant negative correlation between
5hmC level of TSS surrounding regions (±200bp) and gene expression levels in iPS cells
(Supplementary Fig. S3b).
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We also observe bidirectional correlation between 5hmC level and DNA methylation during
reprogramming process. 80% of the partially methylated domains (PMD), which displays
lower levels of CG methylation in somatic cells than stem cells27, have increased 5hmC
levels, with the rest have no 5hmC level change (Fig. 3d). Interestingly, we also found
around 60% stem cells hypoDMRs (lower CG methylation in stem cells) shows increased
5hmC modification (Fig. 3b). Collectively, our results suggest that increased
hydroxymethylation not only occur in loci with increased methylation but also loci with
decreased methylation during reprogramming.
Based on the results of bimodal distribution of 5hmC in TSS and TES, we then determined
whether this distribution is associated with core pluripotency regulatory networks. We found
that pluripotent master regulators, such as OCT3/4 and NANOG, bear this typical
modification in iPSCs but not in fibroblasts (Fig. 3e). We further tested the relation of 5hmC
and key pluripotency factors binding sites27. We found a more than 8-fold higher than
expected overlap between 5hmC-enriched regions and OCT4, KLF4 binding sties, with a
weak association with NANOG and SOX2 binding sites (Fig. 3f). Our results suggest that
OCT4 and KLF4 regulatory networks may require 5hmC to regulate pluripotency during
reprogramming. Furthermore, gene ontology analysis shows that genes acquiring most
5hmC are involved in stem cell differentiation and patterning process (Fig. 3g), suggesting
5hmC in stem cells are highly correlated with pluripotency.
Sequence preferences of 5hmC modification during reprogramming
We compared the CG, CH (CA, CT, CC), CHG preference of hyperDhMRs and
hypoDhMRs. HyperDhMRs tend to be located at higher C and G enriched regions, as well
as CHG and CH enriched regions, whereas hypoDhMRs have the same level as the genome
background (Fig. 3h). Previous observations suggest that 5hmC modification is related to
CpG-density24, 28. We find that in iPSCs, the low CpG content group of CpG islands tend to
have more 5hmC modifications (Supplementary Fig. S3c), which is consistent with the
observation that DNA methylation occurs more frequently in CpG islands with low CpG
content29. Furthermore, 5hmC modifications acquired during reprogramming tend to occur
within the unique sequence in which the methylation is evolutionarily less
conserved30(Supplementary Fig. S3d-f).
Aberrant 5hmC reprogramming hotspots cluster in telomere-proximal regions
Reprogramming of somatic cells to a pluripotent state requires complete reversion of the
somatic epigenome into the pluripotent epigenome, which is an ES-like-state. iPSCs retain
some type of somatic memory from their previous identity31-33. We further determined the
genome-wide 5hmC modification differences between iPS and ES cells, aiming to
understand whether 5hmC modifications underlie the differences between hES cells and iPS
cells. To reduce the biases of tissue origins, we used 9 iPS cells derived from different
origins, 6 of which are from fibroblasts as mentioned earlier, 2 are derived from peripheral
blood cells, and 1 is derived from human exfoliated deciduous teeth cells (SHED).
In general, global DNA hydroxymethylation patterns are very similar between iPS and ES
cells (Fig. 4a). A comprehensive analysis of 372,423 5hmC-enriched regions between 4 hES
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cell and 9 iPS cell lines led to the identification of 113 iPS-ES-DhMRs that were
differentially hydroxymethylated in at least one iPS cell or ES cell line (FDR<0.01), as
shown for the SIGLEC6 and SIGLEC 12 locus in Fig. 5a. Surprisingly, these regions are not
randomly located across the genome; instead, they tend to cluster at the telomere-proximal
regions, in particular, at chromosome 3, 7, 8, 12, and 20 (Fig. 4b).
In contrast to the symmetric pattern of DMRs between iPS and ES cells17, 105 of the 113
iPS-ES DhMRs are hypo-hydroxymethylated, with 5hmC levels similar to their respective
progenitors blood cells or fibroblast (Fig. 4c,d). Of these DhMRs, the 5hmC patterns are
more variable compared with hES cells (Fig. 4d). Unsupervised hierarchical clustering using
the top 1,000 most variable 5hmC modified regions among all samples could not distinguish
hESCs from hiPSCs, suggesting that the variability among iPSCs is not due to different
levels of pluripotency, and the 5hmC deviation of iPSCs is not a key determinant to
distinguish hESCs from iPSCs (Fig. 4e).
Copy number variation (CNV) has been reported to contribute to the variations of
iPSCs34,35. Since DhMRs cluster at subtelomeric regions and shows depletion of
hydroxymethylation, we further examined whether the DhMRs were simply due to genetic
variation, such as CNV, instead of real aberrant 5hmC epigenetic modification. To this end
we used high-density comparative genomic hybridization (aCGH) array to examine 3 iPSCs
and 2 human ESCs. Array CGH yields an average of 70 CNVs on autosomes, none of which
is overlapping with the iPS-ES-DhMRs we identified (Supplementary Fig. S4). Therefore,
iPS-ES-DhMRs are caused by aberrant epigenetic modification.
Concordance of large-scale 5hmC hotspots and iPS-ES non-CG DMRs
Our results suggest that iPS-ES-DhMRs tend to cluster at telomere proximal regions,
forming aberrant reprogramming hotspots. To better define these large-scale regions, we
developed a statistical method to identify potential large-scale aberrant reprogramming
hotspots. An aberrant reprogramming hotspot is defined as a genomic region satisfying the
following conditions: (1) large variability of 5hmC levels among iPS cells, (2) the average
5hmC difference between iPSCs and ESCs is statistically significant, and (3) longer
than100kb. 20 large scale regions were identified. Among them, 19 are hypoDhMRs, all of
which have the same epigenetic status as their parent cells, pointing to a “somatic memory”
during reprogramming, and 1 is hyperDhMRs (Table 1).
We then compared DhMRs with the DMRs identified previously using whole-genome single
base bisulfite sequencing, which would not be able to distinguish 5mC from 5hmC17. Of the
total 113 DhMRs, only 5 overlap with 1,175 CG-DMRs (Fig. 5b). Surprisingly, out of the 19
hypo large-scale hotspots, 84.2% overlap with the 24 mega-scale hypo-non-CG-DMRs,
whereas the expected percentage is 1.6% based on permutation (Fig. 5c). Fig. 5d shows one
of these regions, chr10: 132010002-133270002, 5-mCH are depleted in iPS cells but not
hESC lines; similarly, of the 9 total iPS cells, only iPS-S1 and iPS-S2 derived from blood
bear similar levels of 5hmC compared with hESC counterparts. Of note, the variances from
iPS cells are significantly larger than ES cells (Fig. 6a and Supplementary Fig. S5a, b). None
of the iPS cell lines has all of the 19 hypo large-scale DhMRs restored the same level as the
4 human ES cell lines (Fig. 6b). This indicates that these large-scale regions tend to form
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aberrant reprogramming hotspots that were resistant to reprogramming. We did not observe
a statistically significant (p=0.54) correlation between passage number of iPSCs and the
number of aberrant hotspots (Supplementary Fig. S5c), implying that passage number may
not be a key determinant of hotspots number in each iPSC line.
The aberrant 5hmC reprogramming hotspots we identified may also explain the transcription
level variability in iPSCs. Notably, some of the genes such as TCERG1L and FAM19A
(Table 1), have been reported to be expressed at a significantly lower level in many but not
all iPSCs as compared to ES cells36, 37.
Base-resolution 5hmC analyses reveal large-scale hotspots are mainly caused by aberrant
CG hydroxymethylation
The observed extremely high concordance between hypo large-scale DhMRs and non-CG-
DMRs is surprising, and might indicate that of the previously identified aberrant 5mCH
hotspot regions, a significant portion of CH consists of 5hmC; alternatively, these regions
could contain both non-CG (mC) and CG (hmC) aberrant modification. The majority of
5hmC in ESCs is found at CG sites38. In addition, 5hmC quantification by Tet-Asisted-
Bisulfite sequencing (TAB-Seq) and the chemical capture approach is well correlated both
genome-widely and within the 20 large-scale hotspots regions (Supplementary Fig. S6a,b).
Therefore, it is very likely that the aberrant 5hmC is caused by CG modification.
To test this possibility experimentally, we applied TAB-Seq, which can detect
hydroxymethylation status at base resolution, to 2 hESCs and 4 iPS cell lines. We performed
base-resolution analysis of 5hmC in 3 randomly chosen large-scale regions, chr10, chr18,
chr22, and amplified 5hmC enriched regions by PCR (Fig. 7a and Supplementary Table
S6,7). We then subjected them to deep sequencing. Deep sequencing of PCR amplicons
after traditional bisulfite conversion confirmed that there is epigenetic variation in non-CG
sites but not CG sites (Fig. 7b,d). Consistent with the results obtained by capture method, we
saw the similar 5hmC variations in iPS cells (Fig. 7c and Supplementary Fig. S6c,d).
Importantly, this incomplete hydroxymethylation is caused by CG modification, but not CH
modification (Fig. 7c and Supplementary Fig. S6c,d). For example, in the Chr10 hotspot,
iPS-B22 and B23 show incomplete 5hmC in CG dinucleotides, but not in CH dinucleotides
(Fig. 7e). Therefore, our results suggest the coexistence of aberrant non-CG methylation and
CG aberrant hydroxymethylation in subtelomeric hotspots (Fig. 7f). The concordance of
aberrant CG hydroxymethylation with those aberrant CH large-scale regions suggests there
might be crosstalk between epigenetic pathway regulates hydroxymethylation and pathway
regulates CH methylation; this crosstalk may behave more stochastically in those
subtelomeric regions.
DISCUSSION
Our study suggests that the significant increase of 5hmC during reprogramming is mainly
due to the activation of TET1 protein in human iPS cells, which is in contrast to the previous
observations that both Tet1 and Tet2 are upregulated in mouse iPS cells. Mouse ESCs are
different from human ESCs in many aspects, such as X-chromosome inactivation status in
female lines39. From a cell signaling perspective, human pluripotency (primed pluripotency)
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depends mainly on FGF and Activin-Nodal signaling pathways, whereas mouse
pluripotency (naïve/ground state pluripotency) is maintained by LIF-STAT pathways. The
difference between human and mouse TET family proteins involved in reprogramming may
be caused by FGF signaling selection of a subpopulation of hiPSCs. Several studies of
generating naïve human iPSCs under LIF signaling have been reported40, 41. So it is possible
that TET1 and TET2 have distinct roles in regulating pluripotency, with TET2 being
involved in naïve pluripotency and TET1 functioning in primed pluripotency. On the other
hand, it is possible that TET1-mediated 5hmC modification is unique in human regardless of
different pluripotent stages. Since TET1/2 is dispensable for maintaining stem cells
pluripotency, and their loss are compatible with embryonic and postnatal development42, it
is likely that TET2 expression is not under positive section for stem cell functions during
evolution, thus eventually silenced in human pluripotent stages.
Reprogramming induces a remarkable epigenomic reconfiguration throughout the somatic
cell genome. Recently, it was shown that TET1 and TET2, in synergy with NANOG,
enhance the efficiency of mouse iPS cells reprogramming43. Here we show TET1-mediated
hydroxymethylation change is critical for optimal human iPS cells reprogramming. We
further show that TET1-mediated-5hmC modification only affects reprogramming
efficiency, but does not alter the essential pluripotency in human stem cells. The pathways
involving TET1 regulation largely remain unknown. It would be interesting to know
whether the known epigenetic factors such as DOT1L, Kdm2b, etc 44, 45 which are negative
and positive modulators for reprogramming are linked to TET1-regulated
hydroxymethylation modification.
Human iPS cells hold great promise for regenerative medicine and for establishing models
of specific diseases. iPS and ES cells are known to share key features of pluripotency,
including the expression of pluripotency markers, teratoma formation, cell morphology, the
ability to differentiate into germ layers, and tetraploid complementation46. Two models
depict the equivalence, or lack thereof, between iPSCs and ESCs. One model posits there
may be small but consistent differences between ESCs and iPSCs, as suggested before36, 47;
the other model states that iPSCs and ESCs should be treated as two partially overlapping
groups that share unique features. In this second model, single iPS cell lines cannot be
distinguished from ES cell lines, though iPSCs shows more epigenetic variance. Mounting
evidence supports the latter model16, 17, 32. Therefore, each iPSC may represent a unique
epigenetic status with variable differentiation potential. The cause and degree of variation
remain to be determined. Our study integrates the 5hmC epigenomic mark into the
investigation of ES-iPS equivalence. We find that 5hmC occurs extensively in iPS cells at
levels similar to ES cells, and there are no consistent 5hmC markers that can distinguish
iPSCs from hESCs; however, we identified 20 regions in iPSCs that tend to form large scale
(100kb-1.3Mb) aberrant reprogramming hotspots, supporting the current consensus that
iPSCs are more epigenetically variable than ESCs. Remarkably, these regions with 5hmC
variations tend to cluster in telomere-proximal regions. The close proximity of the hotspots
to telomeres indicates there may be a distinct cellular process that could impede the
reprogramming process.
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Almost none of the DhMRs overlap with CG-DMRs, suggesting CG-DMRs identified
previously are primarily caused by DNA methylation. DNA methylation in non-CG contexts
is abundant in pluripotent stem cells (mCHG and mCHH, where H = A, C or T), comprising
almost 25% of all cytosines at which DNA methylation is identified. Strikingly, ~80% of
large-scale iPS-ES DhMR regions coincide with previously reported non-CG DNA
methylation aberrant hotspots17. Reciprocally, ~50% of non-CG DMRs overlaps with our
identified DhMRs. It was reported that non-CG DMRs also occur in the peri-centromeric
zones. Notably, these peri-centromeric regions contain low level of 5hmC (stem cells have
similar levels of 5hmC as fibroblasts), suggesting cells do not need to establish 5hmC in
these regions during reprogramming (Supplementary Fig. S7). Thus, the concordance occurs
mainly at telomere proximal regions. By applying TAB-Seq, we show that incomplete
hydroxymethylation occur predominantly at CG sites, but not CH sites, suggesting the co-
existence of aberrant non-CG methylation and aberrant CG hydroxymethylation in these
regions. During reprogramming, both CH methylation and hydroxymethylation need to be
established de novo from the somatic epigenome. It is known that non-CG cytosine
methylation is exclusively catalysed by Dnmt3a and Dnmt3b48. The concordance suggests
there might be crosstalk between epigenetics pathways that regulate the activities of TET
and DNMT3, which may behave more stochastically in those subtelomeric regions.
In summary, our results indicate that TET1-mediated 5hmC modification contributes to both
the human iPS cell reprogramming process and differences between iPSCs and hESCs. In
particular, we identified 20 large-scale aberrant hotspots, suggesting iPSCs are more
epigenetically variable than ESCs in terms of 5hmC modification. Our data suggest that,
when studying aberrant epigenetic reprogramming events, as well as their functional
consequences, at the DNA level, 5hmC modification merits particular consideration, in
addition to 5mC.
METHODS
Methods and any associated references are available in the online version of this paper.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TET1 is associated with increased hydroxymethylation during human iPSC reprogramming
(a) Measurement of 5hmC levels in genomic DNAs from fibroblasts, hiPSCs and hESCs by dot blot using anti-5hmC antibody.
Mouse cerebellum genomic DNA was used as a control. 225 ng, 450 ng and 1000 ng DNA were used for each sample. (b)
Quantitative RT-PCR to detect mRNA levels of TET1, TET2, TET3 and NANOG in fibroblasts (CRL2097) and hiPSCs (iPSC-
B21, iPSC-B22). Error bars represent the standard error of the mean (S.E.M.) collected from three independent experiments. (c)
Boxplot of transcript copy numbers of TET1, TET2, TET3, and NANOG in IMR90 (fibroblasts) and H1 (hESCs) represented by
RPKM in RNA-seq. (d) Knocking down TET1 by siRNA significantly decreases 5hmC levels in hiPSCs. Left panel represents
siTET1 knock down efficiency by quantitative RT-PCR (* t-test, p<0.05). Right panel depicts the effect of total 5hmC levels
48hours post siTET1 transfection. Error bars represent S.E.M. collected from three independent experiments. (e) Alkaline
phosphatase (AP) staining of reprogrammed cells treated either with shTET1 lentivirus or an equal titer shControl lentivirus
after O,S,K,M retroviral transduction of 100,000 CRL2097 cells on day 20. Cells used for staining were grown in 10 cm dishes.
The image on the right shows a representative AP positive colony and TET1 transcript level in shTET1- or shControl-treated
cells 10 days post transduction in one representative experiment of three independent experiments. Scale bars: 300 μm. (f)
Summary of quantitative analysis of AP-positive colonies in three different experiments (* t-test, p<0.05). Controls were
normalized to 100%. Error bars represent the standard deviation (SD). (g) Real time PCR analysis of TET1 and pluripotency
marker NANOG. shTET1-treated reprogrammed colonies maintained normal levels of NANOG, but shows decreased TET1
expression (* t-test, p<0.05). Colonies were picked and maintained in puromycin medium (0.5 μg/ml) on puromycin resistant
MEFs. (h) Real time PCR analysis of normalized gene expression levels of TET1 and selected pluripotency related factors in
stable shTET1 or shControl iPS-B22 cells under the puromycin selection (0.5 μg/ml) (*** t-test, p<0.05). Error bars represent
the S.E.M. of three independent experiments. The raw values of related statistical test in this figure are listed in Supplementary
Table S1.
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Figure 2. Reprogramming confers a 5hmC epigenome in a pattern with a bias towards telomere proximal regions in autosomes
(a) Pearson correlation analysis and cluster among fibroblasts and fibroblast derived iPSCs. The values close to 1 indicate
greater similarity. (b) Summary of the numbers of 5hmC differentially modified between fibroblasts and iPSCs, indicated by
hyperDhMR (iPSCs>Fibroblast) and hypoDhMR (iPSCs<Fibroblast). The regions enriched either in fibroblasts or in iPSCs
were subjected to DhMR calling. 5hmC-enriched regions in 3 fibroblast lines and 5 fibroblast-derived iPSC lines were coalesced
into a union window. Then the reads in these windows were recounted and normalized to the total read count from the
respective cell line. 267,664 DhMRs were called with a FDR of 0.01 by the Bioconductor Deseq package, which uses a negative
binomial model for testing differential expression of sequencing data. Among them, 231,866 are hyperDhMRs, and 35,798 are
hypoDhMRs. (c) Composite 5hmC enrichment profile for fibroblasts and iPSCs in the upstream regions of DhMRs, DhMRs,
and downstream regions of DhMRs. The length for upstream and downstream of DhMRs is 5kb. (d) Chromosome ideograms
showing the genome-wide distribution of the top 20,000 Fib-iPSC-DhMRs ranked by lowest adjusted p-value. Blue lines
indicate location of DhMRs. (e) Observed and expected numbers of hyperDhMRs occurring at telomere-proximal regions (chi-
square test, p value<0.00001). Telomere-proximal regions were defined as regions at either end of a chromosome with a length
equal to 1/20th of the total length of that chromosome. The observed number occurring at telomere-proximal regions is called by
overlapping with top 20,000 hyperDhMRs. The expected number is calculated based on the proportion of total telomere-
proximal region length compared to the whole length of all chromosomes. The top 20,000 hyperDhMRs were based on the
5hmC profiles of 3 fibroblast lines and 5 fibroblast-derived iPSC lines. (f) The distribution of the top 20,000 Fib-iPSC-
hyperDhMRs in Chr1 and ChrX.
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Figure 3. 5hmC is associated with gene activity and pluripotency regulatory networks in stem cells
(a) 3 distinct clusters of 5hmC-density pattern at TSS regions (+/− 3kb) in iPSCs and fibroblasts among 9 categories. The 9
categories were classified based on the gene expression changes between iPS cells and fibroblasts: Category 1: high expression
in iPS cells, low expression in fibroblast; Category 2: medium expression in iPS cells, low expression in fibroblast, etc. (b) Box
plots of hydroxymethylation levels in TSS regions and Gene bodies among the three clusters. *** indicates significantly more
5hmC levels compared with all others (P < 0.001, Wilcoxon rank test). Similarly, * indicates lowest 5hmC levels, ** indicated
intermediate 5hmC level. (c) 5hmC enrichment density heatmap. Genes were ordered by expression level from high to low as
determined by H1 RPKM27. The TSS and direction of transcription of genes are indicated by the genomic region from –3kb to
+3kb and an arrow. The TES is indicated by the genomic region from –3kb to +3kb and vertical lines. The left part of the panel
shows genes in fibroblasts, the right part shows the genes in iPSCs. (d) The correlation between PMD (methylation level is
higher in stem cells) and DhMRs, and the correlation between hypoDMRs (methylation level is lower in stem cells) and
DhMRs. (e) 5hmC density at the NANOG locus in input, iPSCs, and fibroblast cell lines. The position of the loci within the
chromosome and the scale are shown above the gene tracks. Black lines indicate the DhMRs. (f) The overlap between NANOG,
OCT4, KLF4, SOX2 binding sites in ES cells and 5hmC significant change regions, shown are observed-to-expected ratios.
Lower panel shows the overlapping percentage of each binding sites. (g) Gene ontology analysis for genes overlapped with most
significant DhMRs. (h) Plot of hyperDhMR and hypoDhMR densities in the context of C+G percent, CG percent, CH percent
and CHG percent.
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Figure 4. Aberrant 5hmC reprogramming hotspots cluster at subtelomeric regions
(a) Pearson correlation analysis and clustering among 9 iPSCs and hESCs. Values close to 1 indicate greater similarity. (b)
Chromosome ideograms showing the genome-wide distribution of 113 iPSC-ES DhMRs. Red lines indicate locations of
DhMRs. (c) The number of iPS-ES-hyperDhMRs and iPS-ES-hypoDhMRs. The 372,423 5hmC-enriched regions either in 9
iPSC lines or 4 hESC lines were subjected to DhMR calling by Bioconductor Deseq package. This analysis led to the
identification of 113 iPS-ES-DhMRs that were differentially hydroxymethylated in at least one iPS cell or ES cell line
(FDR<0.01). 105 of the 113 iPS-ES DhMRs are hypo-hydroxymethylated, with 5hmC levels similar to their respective
progenitors. (d) Complete linkage hierarchical clustering of 5hmC density within the iPS-ES-DhMRs. The raw count values are
scaled by rows during clustering. (e) Hierarchical cluster analysis using the top 1,000 most variable 5hmC enriched regions
across all iPSC and hESC samples. Arrow indicates hESCs.
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Figure 5. 5hmC DhMRs largely overlap with non-CG-DMRs in a large-scale pattern
(a) 5hmC density at the iPS-ES-DhMR SIGLEC6, SIGLEC12 locus, in fibroblast (CRL2097), blood, iPS, and ES cell lines. The
position of the loci within the chromosome and the scale are shown above the gene tracks. Black bars indicate DhMRs. (b) The
number of 5hmC DhMRs that overlaps with CG-DMRs. CG-DMRs were categorized by methylation state relative to the ES
cells. (c) The number of 5hmC large-scale hypoDhMRs that overlap with nonCG-DMRs. NonCG-DMRs were categorized by
methylation state relative to the ES cells reported previously17. The overlap was called if overlapping length is larger than 1 kb.
First bar summarizes the overlap for large-scale hypoDhMRs with hypo-nonCG-DMRs. The second bar summarizes the overlap
for hypo-nonCG-DMRs with large-scale hypoDhMRs. The blue colour represents overlap between nonCG-DMR and
hypoDhMRs. The red colour represents no overlap. (d) 5hmC density at of iPS-ES-DhMR TCERG1L locus in fibroblast
(CRL2097), blood, iPS, and ES cell lines. The position of the loci within the chromosome and the scale are shown above the
gene tracks. Lower parts shows the 5mC levels in CH studied by Lister et al, black colour indicates H1 stem cells, green depicts
iPSCs.
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Figure 6. Large-scale incomplete hydroxymethylation hotspots are characteristics of human iPS cells
(a) Distribution of 20 5hmC large-scale DhMRs in iPSCs and ESs respectively. Green colour: 9 iPS cell relative enrichment
counts, Red colour: 4 hESC cell relative enrichment counts. Solid vertical line separates hyperDhMRs and hypoDhMRs. (b)
Summary of 19 hypo large-scale DhMRs in each iPSC line. Blue colour indicates regions have similar 5hmC level compared
with ES cells, red colour indicates a lower 5hmC level than ES cells. 5hmC levels were determined by counting 5hmC Capture-
Seq reads within each hypo large-scale DhMRs for each cell line. A lower 5hmC level in iPS cells was determined by the
criteria that 5hmC levels were less than three standard deviations from the mean among ES cells; if levels were within three
standard deviations, the region was considered having similar 5hmC levels.
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Figure 7. Large-scale hotspots are caused predominantly by aberrant CpG hydroxymethylation
(a) Summary of PCR based TAB-Seq. (b) 5hmC+5mC single base density in one of the amplicons by traditional bisulfite
sequencing in 2 hESC and 2 iPSC lines. Bisulfite sequencing shows the CH methylation (or methylation plus
hydroxymethylation) variation in iPS cells. The position of the loci within the chromosome and the scale are shown above the
gene tracks. (c) 5hmC single base density on CG sites in 15 amplicons by TAB-Seq in 2 human ES cells 4 iPS cell lines. iPS-
B22 and B23 shows incomplete CG hydroxymethylation. Green colour indicates iPSCs bearing same hydroxymethylation
detected by 5hmC Capture-Seq. Blue colour indicates iPSCs bearing incomplete hydroxymethylation detected by 5hmC
Capture-Seq in this region. (d) 5hmC+5mC single base density in 15 amplicons by traditional bisulfite sequencing in 2 hESC
and 2 iPSC lines. (e) 5hmC single base density on CG dinucleotides and CH dinucleotides in one of the amplicons that are
marked by blackdot in (c) by TAB-Seq in 2 human ES and 4 iPS cell lines. Green colour indicates iPSCs bearing the same
hydroxymethylation detected by 5hmC Capture-Seq. Blue colour indicates iPSCs bearing incomplete hydroxymethylation
detected by 5hmC Capture-Seq in this region. (f) Schematic summary of large scale incomplete hydroxymethylation on CG
dinucleotides in iPS cells.
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Table 1
Summary of large-scale hotspots between iPSCs and hESCs
hypoDhMR(19 regions)
Chr Range(bp) Length (bp) NonCG-DMR Aberrant Lines No. Somatic Memory Genes
Chr1 4533001-5059001 526,001 Y 5 Y AJAP1
Chr3 474001-592001 118,001 N 9 Y Intergenic
Chr3 2515001-2907001 392,001 N 7 Y CNTN4
Chr7 152805001-153016001 211,001 Y 8 Y Intergenic
Chr7 153184001-153312001 128,001 Y 8 Y DPP6
Chr7 153461001-153856001 395,001 Y 6 Y DPP6
Chr7 154010001-154317001 307,001 Y 6 Y DPP6
Chr8 2681001-3289001 608,001 Y 7 Y CSMD1
Chr8 138881001-139209001 328,001 Y 7 Y CSMD1
Chr8 139536001-139818001 282,001 Y 5 Y FAM135B,COL22A1
Chr10 132010001-133270001 1,260,001 Y 7 Y TCERG1L,MIR378c
Chr12 125969001-126071001 102,001 Y 5 Y Intergenic
Chr12 127355001-127814001 459,001 Y 5 Y TMEM132C
Chr16 6803001-7330001 527,001 Y 5 Y RBFOX1
Chr18 73780001-74420001 640,001 N 4 Y Intergenic
Chr20 40395001-40593001 198,001 Y 7 Y PTRPT
Chr20 41004001-41305001 301,001 Y 7 Y PTRPT
Chr20 53591001-53742001 151,001 Y 7 Y Intergenic
Chr22 46433001-46536001 103,001 Y 4 Y Intergenic
hyperDhMR(1 region)
Chr Range Length NonCG-DMR Aberrant Lines No. Somatic Memory Genes
Chr22 46005001-46204000 199000 N 6 Y LOC339685
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